...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Report Of Exempt Distribution.
3
Apr 16, 2024 03:39PM

RVX can fail without affecting Zenith?


Only if you assume the Royalty Preferred Shares will never be worth anything.

tada

Share
New Message
Please login to post a reply